Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study

Table 2

Treatment characteristics of the case group () treated with FCM.

Treatment characteristics
Hb at 1st FCM treatment, g/dL ()^†	8.4 7.7; 8.9]
Hb at 1st FCM treatment, mmol/L ()^†	5.2 4.8; 5.5]
MCV at 1st FCM treatment, fL ()^†	69 62; 76]
Gestational age at 1st treatment, weeks ()^‡	34 + 6 32; 36 + 4]
Gestational age at 2nd treatment, weeks ()^‡	35 + 2 32 + 6; 37 + 3]
Gestational age at 3rd treatment, weeks ()^‡	32 N/E]
Total dose received, mg	1000 1000; 1500]
Treatment-related adverse outcomes reported	0 (0%)
Treatment-related serious adverse outcomes	0 (0%)

Data shown as median IQR] or (%); ^†patients with available data (for remainder of study population not reported); ^‡total number of patients receiving treatment; Hb: hemoglobin; MCV: mean corpuscular volume; IQR: interquartile range.